FormsNet3 - Blank Form


 
 
Sequence Number:    

 
 
Date Received: __ __ __ __ - __ __- __ __  

 
 
CIBMTR Center Number:    

 
 
CIBMTR Recipient ID:    

 
 

Has this patient's data been previously reported to USIDNET?

  
 nmlkji

yes  
 nmlkji

no  

 
 
USIDNET ID:    

 
 
Today's Date: __ __ __ __ - __ __- __ __  

 
 
Date of HSCT for which this form is being completed: __ __ __ __ - __ __- __ __  

 

HSCT type (check all that apply): 

 
  

gfedcb
Autologous

 
 

  
gfedcb

Allogeneic, unrelated

 
 

  
gfedcb

Allogeneic, related

 
 

  
gfedcb

Syngeneic (identical twin)

 

Product type (check all that apply): 

 
  

gfedcb
Marrow

 
 

  
gfedcb

PBSC

 
 

  
gfedcb

Cord blood

 
 

  
gfedcb

Other product

 
 
Specify:    

 
 

  
gfedcb

If this is a report of a second or subsequent transplant, check here and continue with question 67.

 

Disease assessment at diagnosis includes disease characteristics observed within six weeks of the date of diagnosis. 
 
1  What was the date of diagnosis of Wiskott-Aldrich Syndrome (WAS)? __ __ __ __ - __ __- __ __  

 
2  Specify the WAS defining (diagnostic) criteria?

    
 nmlkji

definitive (definitive diagnosis defined as male patient with congenital thrombocytopenia (< 70,000 platelets/mm³), small platelets, and at least one of the additional criteria at 
questions 3-6)  

 nmlkji
probable (probable diagnosis defined as male patient with congenital thrombocytopenia (< 70,000 platelets/mm³), small platelets, and at least one of the additional criteria at 

questions 7-10)  

 nmlkji
possible (possible diagnosis defined as male patient with congenital thrombocytopenia (< 70,000 platelets/mm³) and small platelets; or with splenectomy for 

thrombocytopenia and at least one of the additional criteria at questions 7-10)  

 

Specify all additional criteria for definitive WAS diagnosis: 
 

3  Mutation in WASp

    
 nmlkji

yes  
 nmlkji

no  

 
 

4  Absent WASp mRNA on northern blot analysis of lymphocytes

    
 nmlkji

yes  
 nmlkji

no  

 
 

5  Absent WASp protein in lymphocytes

    
 nmlkji

yes  
 nmlkji

no  

 
 

6  Maternal cousins, uncles, or nephews with small platelets and thrombocytopenia

    
 nmlkji

yes  
 nmlkji

no  

  Key Fields 

Disease Assessment at Diagnosis Questions: 1 - 13

Form 2033 R3.0: Wiskott-Aldrich Syndrome Pre-HSCT Data  
Center:  CRID: 

             CIBMTR Form 2033 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 1 / 10



 

Specify all additional criteria for probable / possible WAS diagnosis: 
 

7  Eczema

    
 nmlkji

yes  
 nmlkji

no  

 
 

8  Abnormal antibody response to polysaccharide antigens

    
 nmlkji

yes  
 nmlkji

no  

 
 

9  Autoimmune disease(s)

    
 nmlkji

yes  
 nmlkji

no  

 
 

10  Lymphoma / Leukemia

    
 nmlkji

yes  
 nmlkji

no  

 
 

11  Was a WAS gene mutation identified?

    
 nmlkji

yes  
 nmlkji

no  

 
 

12  Specify gene mutation identified:

    
 nmlkji

nucleotides affected (e.g., 361C>T)  

 nmlkji
predicted amino acid change (e.g., W14R)  

 
 

13  Was a WASp protein expressed?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
14  Date CBC tested: (testing done within 6 weeks of diagnosis) __ __ __ __ - __ __- __ __  

  
 
15  WBC:    

 

  
 nmlkji

x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

  
gfedcb

WBC not tested

  
 
16  Lymphocytes:    % 

 
  

gfedcb
Lymphocytes not tested

  
 
17  Eosinophils:    % 

 
  

gfedcb
Eosinophils not tested

  
 
18  Polymorphonuclear leukocytes (PMN):    % 

 
  

gfedcb
Polymorphonuclear leukocytes (PMN) not tested

  
 
19  Hemoglobin:    

 

  
 nmlkji

g/dL  
 nmlkji

g/L  
 nmlkji

mmol/L  

 
 

  
gfedcb

Hemoglobin not tested

 
 

  
gfedcb

transfused RBC < 30 days from date of test

  
 
20  Platelets:    

 

  
 nmlkji

x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

  
gfedcb

Platelets not tested

 
 

  
gfedcb

transfused platelets < 7 days from date of test

  
 
21  Mean platelet volume:    fl 

 
  

gfedcb
Mean platelet volume not tested

Laboratory Studies at Diagnosis Questions: 14 - 41

Form 2033 R3.0: Wiskott-Aldrich Syndrome Pre-HSCT Data  
Center:  CRID: 

             CIBMTR Form 2033 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 2 / 10



  

Immunoglobulin Analysis 

Specify the following quantitative immunoglobulins measured prior to any disease treatment: 

 
22  IgG:    

 

  
 nmlkji

mg/dL  
 nmlkji

g/dL  
 nmlkji

g/L  

 
 

  
gfedcb

IgG not tested

 
 
23  Date tested: __ __ __ __ - __ __- __ __  

  
 
24  IgM:    

 

  
 nmlkji

mg/dL  
 nmlkji

g/dL  
 nmlkji

g/L  

 
 

  
gfedcb

IgM not tested

 
 
25  Date tested: __ __ __ __ - __ __- __ __  

  
 
26  IgA:    

 

  
 nmlkji

mg/dL  
 nmlkji

g/dL  
 nmlkji

g/L  

 
 

  
gfedcb

IgA not tested

 
 
27  Date tested: __ __ __ __ - __ __- __ __  

  
 
28  IgE:    IU/mL 

 
  

gfedcb
IgE not tested

 
 
29  Date tested: __ __ __ __ - __ __- __ __  

 
 

30  Did the recipient receive supplemental intravenous immunoglobulins (IVIG) prior to any first treatment of WAS?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

31  Was therapy ongoing within one month of immunoglobulin testing?

    
 nmlkji

yes  
 nmlkji

no  

 

Lymphocyte Analysis 

Specify the following lymphocyte analyses performed prior to any disease treatment: 

 
32  Were lymphocyte analyses performed?

    
 nmlkji

yes  
 nmlkji

no  

 
 
33  Date of most recent testing performed: __ __ __ __ - __ __- __ __  

 
 
34  Absolute lymphocyte count:    cells /µL (cells / mm

3
) 

 
 
35  CD3 (T cells) % of total lymphocytes    % 

  

-- or -- 
 
CD3 (T cells) value    

 

  
 nmlkji

x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

  
gfedcb

CD3 (T cells) not tested

 
 
36  CD4 (T helper cells) % of total lymphocytes    % 

  

-- or -- 
 
CD4 (T helper cells) value    

 

  
 nmlkji

x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

  
gfedcb

CD4 (T helper cells) not tested

 
 
37  CD8 (cytotoxic T cells) % of total lymphocytes    % 

Form 2033 R3.0: Wiskott-Aldrich Syndrome Pre-HSCT Data  
Center:  CRID: 

             CIBMTR Form 2033 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 3 / 10



  

-- or -- 
 
CD8 (cytotoxic T cells) value    

 

  
 nmlkji

x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

  
gfedcb

CD8 (cytotoxic T cells) not tested

 
 
38  CD20 (B lymphocyte cells) % of total lymphocytes    % 

  

-- or -- 
 
CD20 (B lymphocyte cells) value    

 

  
 nmlkji

x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

  
gfedcb

CD20 (B lymphocyte cells) not tested

 
 
39  CD56 (natural killer (NK) cells) % of total lymphocytes    % 

  

-- or -- 
 
CD56 (natural killer (NK) cells) value    

 

  
 nmlkji

x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

  
gfedcb

CD56 (natural killer (NK) cells) not tested

 
 
40  CD4+/CD45RA+ (naive T cells) % of total lymphocytes    % 

  

-- or -- 
 
CD4+/CD45RA+ (naive T cells) value    

 

  
 nmlkji

x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

  
gfedcb

CD4+ / CD45RA+ (naive T cells) not tested

 
 
41  CD4+/CD45RO+ (memory T cells) % of total lymphocytes    % 

  

-- or -- 
 
CD4+/CD45RO+ (memory T cells) value    

 

  
 nmlkji

x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

  
gfedcb

CD4+/CD45RO+ (memory T cells) not tested

 
 

42  Site of infection: hepatitis

    
 nmlkji

yes  
 nmlkji

no  

 
 
43  Organism   

 
 
44  Specify other organism :    

 
 

45  If hepatitis was present, was it a prominent feature of WAS?

    
 nmlkji

yes  
 nmlkji

no  

Clinical Features Assessed between Diagnosis and the Start of the Preparative Regimen Questions: 42 - 143

  Hepatitis Infection Organism (1) Questions: 43 - 44 

Form 2033 R3.0: Wiskott-Aldrich Syndrome Pre-HSCT Data  
Center:  CRID: 

             CIBMTR Form 2033 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 4 / 10



 
 

46  Site of infection: meningitis / encephalitis

    
 nmlkji

yes  
 nmlkji

no  

 
 
47  Organism   

 
 
48  Specify other organism:    

 
 

49  If meningitis / encephalitis was present, was it a prominent feature of WAS?

    
 nmlkji

yes  
 nmlkji

no  

 
 

50  Site of infection: pneumonia

    
 nmlkji

yes  
 nmlkji

no  

 
 
51  Organism   

 
 
52  Specify other organism :    

 
 

53  If pneumonia was present, was it a prominent feature of WAS?

    
 nmlkji

yes  
 nmlkji

no  

 
 

54  Site of infection: severe or protracted diarrhea

    
 nmlkji

yes  
 nmlkji

no  

 
 
55  Organism   

 
 
56  Specify other organism:    

 
 

57  If diarrhea was present, was it a prominent feature of WAS?

    
 nmlkji

yes  
 nmlkji

no  

 
 

58  Site of infection: systemic infection

    
 nmlkji

yes  
 nmlkji

no  

 
 
59  Organism   

 
 
60  Specify other organism :    

 
 

61  If systemic infection was present, was it a prominent feature of WAS?

    
 nmlkji

yes  
 nmlkji

no  

 
 

62  Site of infection: other infection

    
 nmlkji

yes  
 nmlkji

no  

 
 
63  Organism   

 
 
64  Specify other organism :    

 
 
65  Specify other infection site:    

 
 

66  If other infection was present, was it a prominent feature of WAS?

    
 nmlkji

yes  
 nmlkji

no  

  Meningitis / Encephalitis Infection Organism (1) Questions: 47 - 48 

  Pneumonia Infection Organism (1) Questions: 51 - 52 

  Severe or Protracted Diarrhea Infection Organism (1) Questions: 55 - 56 

  Systemic Infection Infection Organism (1) Questions: 59 - 60 

  Other Infection Organism (1) Questions: 63 - 65 

Form 2033 R3.0: Wiskott-Aldrich Syndrome Pre-HSCT Data  
Center:  CRID: 

             CIBMTR Form 2033 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 5 / 10



 

Clinical Status between Diagnosis and the Preparative Regimen 
 

67  Did the recipient undergo a splenectomy (between diagnosis and prior to the preparative regimen)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
68  Specify the date the splenectomy was performed: __ __ __ __ - __ __- __ __  

  
 
69  Platelets (after splenectomy):    

 
.

  
 nmlkji

x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

  
gfedcb

Platelets (after splenectomy) not tested

 
 

  
gfedcb

transfused platelets < 7 days from date of test

 
70  Were thrombocytopenia (<100 x 109/L) and small platelets present without any other symptoms, clinical findings, or laboratory abnormalities attributable to WAS (between diagnosis 

and prior to the preparative regimen)? 

    
 nmlkji

yes  -Specify thrombocytopenia in the Form 2000 Recipient Baseline Data at questions 117-118 

 nmlkji
no  

 nmlkji
Unknown  

 
 

71  Was eczema present as a clinical feature (between diagnosis and prior to the preparative regimen)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

72  Specify severity of eczema:

    
 nmlkji

mild, transient  

 nmlkji
persistent but manageable  

 nmlkji
difficult to control  

 
 

73  Was a coexisiting malignancy present (between diagnosis and prior to the preparative regimen)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
74  Specify malignancy:    

 

Report malignancy in the Form 2000 — Recipient Baseline Data at questions 22–60 
 

75  Did the recipient experience any of the following types of bleeding episodes (between diagnosis and prior to the preparative regimen)?

    
 nmlkji

yes  
 nmlkji

no  

 
 

76  Is epistaxis present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

77  Is epistaxis prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

78  Is upper GI hemorrhage present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

79  Is upper GI hemorrhage prominent?

    
 nmlkji

yes  -Report GI hemorrhage in the Form 2000 — Recipient Baseline Data at question 63 

 nmlkji
no  

 
 

80  Is lower GI hemorrhage/rectal bleeding present?

    
 nmlkji

yes  
 nmlkji

no  

Form 2033 R3.0: Wiskott-Aldrich Syndrome Pre-HSCT Data  
Center:  CRID: 

             CIBMTR Form 2033 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 6 / 10



 
 

81  Is lower GI hemorrhage/rectal bleeding prominent?

    
 nmlkji

yes  -Report GU hemorrhage in the Form 2000 — Recipient Baseline Data at question 64 

 nmlkji
no  

 
 

82  Is hemarthrosis present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

83  Is hemarthrosis prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

84  Is hematuria present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

85  Is hematuria prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

86  Is intracranial hemorrhage present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

87  Is intracranial hemorrhage prominent?

    
 nmlkji

yes  -Report CNS hemorrhage in the Form 2000 Recipient Baseline Data at question 65 

 nmlkji
no  

 
 

88  Is oral bleeding present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

89  Is oral bleeding prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

90  Is subcutaneous bleeding present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

91  Is subcutaneous bleeding prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

92  Is subdural hematoma present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

93  Is subdural hematoma prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

94  Is other bleeding present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

95  Is other bleeding prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 
96  Specify other bleeding:    

 
 

97  Did the recipient experience any of the following autoimmune / inflammatory disorders (between diagnosis and prior the preparative regimen?)

    
 nmlkji

yes  
 nmlkji

no  

 

Specify autoimmune / inflammatory disorders: 
 

98  Is arthralgia present?

    
 nmlkji

yes  
 nmlkji

no  

Form 2033 R3.0: Wiskott-Aldrich Syndrome Pre-HSCT Data  
Center:  CRID: 

             CIBMTR Form 2033 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 7 / 10



 
 

99  Is arthralgia prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

100  Is chronic arthritis present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

101  Is chronic arthritis prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

102  Is autoimmune hemolytic anemia present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

103  Is autoimmune hemolytic anemia prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

104  Is idiopathic thrombocytopenic purpura (ITP) present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

105  Is idiopathic thrombocytopenic purpura (ITP) prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

106  Is inflammatory bowel disease present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

107  Is inflammatory bowel disease prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

108  Is juvenile rheumatoid arthritis present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

109  Is juvenille rheumatoid arthritis prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

110  Is nephritis present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

111  Is nephritis prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

112  Is neutropenia present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

113  Is neutropenia prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

114  Is sclerosing cholangitis present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

115  Is sclerosing cholangitis prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

116  Is cerebral vasculitis present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

117  Is cerebral vasculitis present?

    
 nmlkji

yes  
 nmlkji

no  

Form 2033 R3.0: Wiskott-Aldrich Syndrome Pre-HSCT Data  
Center:  CRID: 

             CIBMTR Form 2033 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 8 / 10



 
 

118  Is coronary vasculitis present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

119  Is coronary vasculitis prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

120  Is renal vasculitis present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

121  Is renal vasculitis prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

122  Is skin vasculitis present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

123  Is skin vasculitis prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

124  Is other vasculitis present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

125  Is other vasculitis prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 
126  Specify other vasculitis:    

 
 

127  Other disorder

    
 nmlkji

yes  
 nmlkji

no  

 
 

128  Is any other disorder prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 
129  Specify other disorder:    

 
 

130  Were any biologic specimens collected for this recipient (between the date of diagnosis and the preparative regimen)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify if specimen(s) collected and available for future research: 
 

131  DNA

    
 nmlkji

yes  
 nmlkji

no  

 
 

132  Epstein-Barr virus (EBV)-transformed B-Cell line

    
 nmlkji

yes  
 nmlkji

no  

 
 

133  Fibroblast cell line

    
 nmlkji

yes  
 nmlkji

no  

 
 

134  Herpes virus saimiri-transformed T-cell line

    
 nmlkji

yes  
 nmlkji

no  

 
 

135  Other T-cell line

    
 nmlkji

yes  
 nmlkji

no  

 
 

136  Pathological specimen

    
 nmlkji

yes  
 nmlkji

no  

 
 
137  Specify pathological specimen(s):    

Form 2033 R3.0: Wiskott-Aldrich Syndrome Pre-HSCT Data  
Center:  CRID: 

             CIBMTR Form 2033 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 9 / 10



 
 

138  Peripheral blood mononuclear cells (PBMC), frozen

    
 nmlkji

yes  
 nmlkji

no  

 
 

139  RNA

    
 nmlkji

yes  
 nmlkji

no  

 
 
140  Specify RNA source:    

 
 

141  Serum (pre-IVIG)

    
 nmlkji

yes  
 nmlkji

no  

 
 

142  Other specimen

    
 nmlkji

yes  
 nmlkji

no  

 
 
143  Specify other specimen(s):    

  
 
First Name:    

 
Last Name:    

  
 
Phone:    

 
Fax:    

 
 
E-mail address:    

Form 2033 R3.0: Wiskott-Aldrich Syndrome Pre-HSCT Data  
Center:  CRID: 

             CIBMTR Form 2033 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 10 / 10